A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles

International Immunology

Volumn 22, Issue 11, 2010, Pages 863-873

  Butler, Marcus O ^a,b,c   Ansén, Sascha ^a,b,c   Tanaka, Makito ^a,b,c   Imataki, Osamu ^a,b,c   Berezovskaya, Alla ^a   Mooney, Mary M ^a   Metzler, Genita ^a   Milstein, Matthew I ^a   Nadler, Lee M ^a,b,c   Hirano, Naoto ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adoptive therapy; Artificial APC; CD4; Foxp3; HLA DR; K562

Indexed keywords

B7 ANTIGEN; CD64 ANTIGEN; HLA A2 ANTIGEN; HLA DM ANTIGEN; PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ALLELE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL LINE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENDOCYTOSIS; EX VIVO STUDY; EXPERIMENT; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNITY; LEUKEMIA CELL; LEUKOCYTE FUNCTION; MEMORY; MOLECULE; PHENOTYPE; PRIORITY JOURNAL; TUMOR;

ALLELES; ANTIGEN-PRESENTING CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; HLA-DR ANTIGENS; HUMANS;

EID: 78649789084     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxq440     Document Type: Article

References (52)

1. June, C. H. 2007. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117:1466.
2. Leen, A. M., Rooney, C. M. and Foster, A. E. 2007. Improving T cell therapy for cancer. Annu. Rev. Immunol. 25:243.
3. Rosenberg, S. A. and Dudley, M. E. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21:233
4. Berger, C., Turtle, C. J., Jensen, M. C. and Riddell, S. R. 2009. Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr. Opin. Immunol. 21:224.
5. Bollard, C. M., Gottschalk, S., Leen, A. M. et al. 2007. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110:2838.
6. Dudley, M. E., Yang, J. C., Sherry, R. et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26:5233
7. Hunder, N. N., Wallen, H., Cao, J. et al. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NYESO-1. N. Engl J. Med. 358:2698.
8. Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J. and Andreesen, R. 2006. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24:5060.
9. Morgan, R. A., Dudley, M. E., Wunderlich, J. R. et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126.
10. Pule, M. A., Savoldo, B., Myers, G. D. et al. 2008. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14:1264.
11. Walter, E. A., Greenberg, P. D., Gilbert, M. J. et al. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038.
12. Muranski, P. and Restifo, N. P. 2009. Adoptive immunotherapy of cancer using CD4+ T cells. Curr. Opin. Immunol. 21:200.
13. Hirano, N., Butler, M. O., Xia, Z. et al. 2006. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107:1528.
14. Butler, M. O., Lee, J. S., Ansen, S. et al. 2007. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin. Cancer Res. 13:1857.
15. Hirano, N., Butler, M. O., Xia, Z. et al. 2006. Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood 108:2662.
16. Hirano, N., Butler, M. O., Xia, Z. et al. 2006. Efficient presentation of naturally processed HLA class I peptides by artificial antigenpresenting cells for the generation of effective antitumor responses. Clin. Cancer Res. 12:2967.
17. Butler, M., Friedlander, P., Mooney, M. et al. 2009. Establishing CD8(+) T cell immunity by adoptive transfer of autologous, IL-15 expanded, anti-tumor CTL with a central/effector memory phenotype can induce objective clinical responses. Blood 114:323.
18. Prazma, C. M., Yazawa, N., Fujimoto, Y., Fujimoto, M. and Tedder, T. F. 2007. CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo. J. Immunol. 179:4550.
19. Ansen, S., Butler, M. O., Berezovskaya, A. et al. 2008. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin. Cancer Res. 14:6125.
20. Hirano, N., Butler, M. O., Von Bergwelt-Baildon, M. S. et al. 2003. Autoantibodies frequently detected in patients with aplastic anemia. Blood 102:4567.
21. Hirano, N., Butler, M. O., Guinan, E. C., Nadler, L. M. and Kojima, S. 2005. Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br. J. Haematol. 128:221.
22. Bunce, M., O'Neill, C. M., Barnardo, M. C. et al. 1995. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46:355.
23. Alexander, J., Sidney, J., Southwood, S. et al. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751.
24. Hirano, N., Takahashi, T., Ohtake, S. et al. 1996. Expression of costimulatory molecules in human leukemias. Leukemia 10:1168.
25. Papadimitriou, L., Morianos, I., Michailidou, V., Dionyssopoulou, E., Vassiliadis, S. and Athanassakis, I. 2008. Characterization of intracellular HLA-DR, DM and DO profile in K562 and HL-60 leukemic cells. Mol. Immunol. 45:3965.
26. Bryant, P. and Ploegh, H. 2004. Class II MHC peptide loading by the professionals. Curr. Opin. Immunol. 16:96.
27. Karlsson, L. 2005. DM and DO shape the repertoire of peptide-MHC-class-II complexes. Curr. Opin. Immunol. 17:65.
28. Warmerdam, P. A., van de Winkel, J. G., Gosselin, E. J. and Capel, P. J. 1990. Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J. Exp. Med. 172:19.
29. Suhoski, M. M., Golovina, T. N., Aqui, N. A. et al. 2007. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol. Ther. 15: 981.
30. Daëron, M. 1997. Fc RECEPTOR BIOLOGY. Ann. Rev. Immunol. 15:203.
31. Khattab, B. A., Lindenmaier, W., Frank, R. and Link, H. 1997. Three T-cell epitopes within the C-terminal 265 amino acids of the matrix protein pp65 of human cytomegalovirus recognized by human lymphocytes. J. Med. Virol. 52:68.
32. Li Pira, G., Bottone, L., Ivaldi, F. et al. 2004. Identification of new Th peptides from the cytomegalovirus protein pp65 to design a peptide library for generation of CD4 T cell lines for cellular immunoreconstitution. Int. Immunol. 16:635.
33. Trivedi, D., Williams, R. Y., O'Reilly, R. J. and Koehne, G. 2005. Generation of CMV-specific T lymphocytes using proteinspanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood 105:2793.
34. Bronke, C., Palmer, N. M., Westerlaken, G. H. A. et al. 2005. Direct ex vivo detection of HLA-DR3-restricted cytomegalovirus- and mycobacterium tuberculosis-specific CD4+ T cells. Human Immunol. 66:950.
35. Kern, F., Bunde, T., Faulhaber, N. et al. 2002. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 185:1709.
36. Weekes, M. P., Wills, M. R., Sissons, J. G. P. and Carmichael, A. J. 2004. Long-term stable expanded human CD4+ T cell clones specific for human cytomegalovirus are distributed in both CD45RAhigh and CD45ROhigh populations. J. Immunol. 173:5843.
37. Gallot, G., Vivien, R., Ibisch, C. et al. 2001. Purification of Agspecific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD25 selection. I. Application to CD4+ or CD8+ cytomegalovirus phosphoprotein pp65 epitope determination. J. Immunol. 167:4196.
38. Harcourt, G. C., Scriba, T. J., Semmo, N., Bounds, S., Taylor, E. and Klenerman, P. 2006. Identification of key peptide-specific CD4+ T cell responses to human cytomegalovirus: implications for tracking antiviral populations. Clin. Exp. Immunol. 146:203.
39. Ghei, M., Stroncek, D. F. and Provenzano, M. 2005. Analysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides. J. Transl. Med. 3:23.
40. Provenzano, M., Lim, J. B., Mocellin, S. et al. 2003. The matrix protein pp65(341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele. Transfusion 43:1567.
41. June, C. H. and Blazar, B. R. 2006. Clinical application of expanded CD4(+)25(+) cells. Semin. Immunol. 18:78.
42. Masteller, E. L., Tang, Q. and Bluestone, J. A. 2006. Antigenspecific regulatory T cells-ex vivo expansion and therapeutic potential. Semin. Immunol. 18:103.
43. Chen, W. and Wahl, S. M. 2003. TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev. 14:85.
44. Hoglund, P. 2006. Induced peripheral regulatory T cells: the family grows larger. Eur. J. Immunol. 36:264.
45. Walker, M. R., Kasprowicz, D. J., Gersuk, V. H. et al. 2003. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J. Clin. Invest. 112:1437.
46. Nakanishi, Y., Lu, B., Gerard, C. and Iwasaki, A. 2009. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462:510.
47. Knutson, K. L. and Disis, M. L. 2005. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54:721.
48. Kennedy, R. and Celis, E. 2008. Multiple roles for CD4+T cells in anti-tumor immune responses. Immunol. Rev. 222:129.
49. Klitz, W., Maiers, M., Spellman, S. et al. 2003. New HLA haplotype frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. Tissue Antigens 62:296.
50. Zachary, A. A., Bias, W. B., Johnson, A., Rose, S. M. and Leffell, M. S. 2001. Antigen, allele, and haplotype frequencies report of the ASHI minority antigens workshops: part 1, African-Americans. Hum. Immunol. 62:1127.
51. Li, M. O. and Flavell, R. A. 2008. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 28:468.
52. Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K. 2009. IL-17 and Th17 cells. Ann. Rev. Immunol. 27:485.